Nocebo phenomena may be enhanced in aging: Implications for clinical practice

被引：10
作者：
Kravvariti, E. [1 ]
Kotsani, M. [2 ]
Mitsikostas, D. D. [3 ]
Sfikakis, P. P. [1 ]
机构：
[1] Natl & Kapodistrian Univ Athens, Postgrad Med Studies Physiol Aging & Geriatr Synd, Med Sch, Athens, Greece
[2] Univ Lorraine, CHRU Nancy, Pole Malad Vieillissement Gerontol & Soins Pallia, F-54000 Nancy, France
[3] Natl & Kapodistrian Univ Athens, Aeginit Hosp, Dept Neurol 1, Sch Med, Athens, Greece
来源：
MATURITAS | 2021年 / 143卷
关键词：
Nocebo; Nocebo effects; Older adults; Geriatric care; Medication adverse effects; Negative treatment expectations; ALZHEIMERS-DISEASE; ELDERLY-PATIENTS; ADVERSE EVENTS; OLDER PATIENTS; PLACEBO; TRIALS; MECHANISMS; CARE; PERCEPTIONS; DEPRESSION;
D O I：
10.1016/j.maturitas.2020.07.011
中图分类号：
R592 [老年病学]; C [社会科学总论];
学科分类号：
03 ; 0303 ; 100203 ;
摘要：
Nocebo effects, denoting unfavourable outcomes after a medical intervention because of negative expectations rather than a direct pharmacologic action, are an important cause of dropout from clinical trials and nonadherence to medication, and may be especially pertinent for older adults. Several characteristics of aging individuals and their medical care have a potential to augment nocebo susceptibility, such as depression and anxiety, neurodegenerative diseases and chronic pain states, adverse healthcare experiences, generic drug use, age-related stereotypes, and strained patient-physician communication. Nocebo-related research in older adults is hindered by under-representation in clinical trials, medical complexity of geriatric patients, and lack of validated tools to accurately assess susceptibility and efficacy of preventive efforts.
引用
收藏
页码：10 / 16
页数：7
相关论文
共 69 条
[11]  
Carlino E, 2016, HAND CLINIC, V139, P597, DOI 10.1016/B978-0-12-801772-2.00048-5
[12]   Can knowledge of Placebo and Nocebo Mechanisms Help Improve Randomized Clinical Trials? [J].
Carlino, Elisa ;
Vase, Lene .
NEUROBIOLOGY OF THE PLACEBO EFFECT, PT I, 2018, 138 :329-357
[13]  
Casado J., 2016, Revista Espanola de Geriatria y Gerontologia, V51, P270, DOI DOI 10.1016/J.REGG.2016.03.005
[14]   Use of ClinicalTrials.gov to Estimate Condition-Specific Nocebo Effects and Other Factors Affecting Outcomes of Analgesic Trials [J].
Cepeda, M. Soledad ;
Lobanov, Victor ;
Berlin, Jesse A. .
JOURNAL OF PAIN, 2013, 14 (04) :405-411
[15]   Overt versus covert treatment for pain, anxiety, and Parkinson's disease [J].
Colloca, L ;
Lopiano, L ;
Lanotte, M ;
Benedetti, F .
LANCET NEUROLOGY, 2004, 3 (11) :679-684
[16]   Nocebo Effects, Patient-Clinician Communication, and Therapeutic Outcomes [J].
Colloca, Luana ;
Finniss, Damien .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2012, 307 (06) :567-568
[17]   Placebo and Nocebo Effects in Randomized Double-Blind Clinical Trials of Agents for the Therapy for Fatigue in Patients With Advanced Cancer [J].
de la Cruz, Maxine ;
Hui, David ;
Parsons, Henrique A. ;
Bruera, Eduardo .
CANCER, 2010, 116 (03) :766-774
[18]   The power and value of placebo and nocebo in painful osteoarthritis [J].
Dieppe, P. ;
Goldingay, S. ;
Greville-Harris, M. .
OSTEOARTHRITIS AND CARTILAGE, 2016, 24 (11) :1850-1857
[19]   Physician and pharmacist perceptions of generic medicines: What they think and how they differ [J].
Dunne, Suzanne ;
Shannon, Bill ;
Hannigan, Ailish ;
Dunne, Colum ;
Cullen, Walter .
HEALTH POLICY, 2014, 116 (2-3) :214-223
[20]   Medication Use for Comorbidities in People with Alzheimer's Disease: An Australian Population-Based Study [J].
Eshetie, Tesfahun C. ;
Nguyen, Tuan A. ;
Gillam, Marianne H. ;
Kalisch Ellett, Lisa M. .
PHARMACOTHERAPY, 2019, 39 (12) :1146-1156
1234567